Major Investor OrbiMed Reduces Stake in MBX Biosciences Below 10%

summarizeSummary

OrbiMed Advisors and its affiliated funds reported a reduction in their beneficial ownership of MBX Biosciences to 7.7%, primarily due to dilution from a recent ATM offering and active share sales totaling approximately $12.74 million.

check_boxKey Events

• OrbiMed's Stake Reduced

  OrbiMed Advisors and its affiliated funds now beneficially own 7.7% of MBX Biosciences' common stock, down from an implied previous stake above 8.7%.

• Significant Share Sales

  OrbiMed funds sold approximately 364,000 shares between December 26, 2025, and January 16, 2026, for an estimated total value of $12.74 million.

• Dilution from ATM Offering

  The reduction in percentage ownership was partly driven by the increase in outstanding shares from MBX Biosciences' at-the-market offering, which was completed on February 5, 2026.

• Retains Registration Rights

  OrbiMed continues to hold demand, Form S-3, and piggyback registration rights, allowing them to request the company to register their shares for sale in the future.

auto_awesomeAnalysis

This Schedule 13D/A filing indicates that OrbiMed, a significant institutional investor, has reduced its beneficial ownership in MBX Biosciences to 7.7%. The decrease in percentage ownership is attributed to the company's recent at-the-market (ATM) offering, which increased the total number of outstanding shares, as well as active sales by OrbiMed's funds between late December 2025 and mid-January 2026. The sales, totaling approximately $12.74 million, represent a notable disposition by a major shareholder. While the ATM offering was previously disclosed, the specific details of OrbiMed's sales and the resulting ownership percentage are new and signal a reduction in conviction or a portfolio rebalancing by a key investor.